id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-333200-yka7wfbi	Dhampalwar, Swapnil	Treatment armamentarium of COVID-19: Evolving strategies & evidence so far	2020-07-16		.txt	text/plain	1253	82	48	Keeping up with this current pace of information, we review the clinical studies of different therapeutic options available to treat SARS-CoV-2. (20) Since, these studies with CQ & HCQ have different therapeutic regimens, heterogenous study population, unequal arms to compare, ill-defined outcomes, and non-reproducible results; further randomized trials are needed before recommending the routine use of HCQ in mild COVID-19. Since Favipiravir and Lopinavir-ritonavir did not provide significant benefits in viral clearance or clinical improvement in severe disease, further randomized trials are necessary before recommending these drugs in clinical practice. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection	./cache/cord-333200-yka7wfbi.txt	./txt/cord-333200-yka7wfbi.txt